Deutsch English Français

Contact

EP1083924

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1083924

EP1083924 - GLUCAGON-LIKE PEPTIDE-1 (GLP-1) IMPROVES BETA-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE [Right-click to bookmark this link]
Former [2001/12]	GLUCAGON-LIKE PEPTIDE-1 IMPROVES BETA-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE
	[2003/33]
Status	Patent revoked Status updated on 17.03.2006 Database last updated on 16.11.2024
Most recent event Tooltip	11.07.2008	Change - opposition data/opponents data or that of the opponents representative	published on 13.08.2008 [2008/33]
Applicant(s)	For all designated states AMYLIN PHARMACEUTICALS, INC. 9373 Towne Centre Drive, Suite 250 San Diego California 92121 / US
	[N/P]
Former [2003/36]	For all designated states AMYLIN PHARMACEUTICALS, INC. 9373 Towne Centre Drive, Suite 250 San Diego California 92121 / US
Former [2001/12]	For all designated states BIONEBRASKA, INC. 3820 N.W. 46th Street Lincoln, NB 68524 / US
Inventor(s)	01 / GOKE, Burkhard Mariborer Strasse 22 D-35037 Marburg / DE
	02 / BYRNE, Maria 3820 N.W. 46th Street Lincoln, NE 68524 / US
	03 / COOLIDGE; Thomas, R. 3820 N.W: 46th Street Lincoln, NE 68524 / US
	[2001/12]
Representative(s)	Thomson, Paul Anthony, et al Potts, Kerr & Co. 15, Hamilton Square Birkenhead Merseyside CH41 6BR / GB
	[N/P]
Former [2003/36]	Thomson, Paul Anthony, et al Potts, Kerr & Co. 15, Hamilton Square Birkenhead Merseyside CH41 6BR / GB
Former [2001/12]	Thomson, Paul Anthony Potts, Kerr & Co. 15, Hamilton Square Birkenhead Merseyside L41 6BR / GB
Application number, filing date	99921778.9	07.05.1999
	[2001/12]
	WO1999US10040
Priority number, date	US19980089044P	12.06.1998 Original published format: US 89044 P
	[2001/12]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO9964061
	Date:	16.12.1999
	Language:	EN
	[1999/50]
	Type:	A1 Application with search report
	No.:	EP1083924
	Date:	21.03.2001
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 16.12.1999 takes the place of the publication of the European patent application.
	[2001/12]
	Type:	B1 Patent specification
	No.:	EP1083924
	Date:	14.07.2004
	Language:	EN
	[2004/29]
Search report(s)	International search report - published on:	EP	16.12.1999
Classification	IPC:	A61K38/26	[2001/12]
	CPC:	A61K38/2278 (EP,US); A61K38/26 (EP,KR,US); A61P3/00 (EP); A61P3/08 (EP); A61P3/10 (EP); A61P43/00 (EP); (+) A61P9/00 (EP) (-)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2001/12]
Title	German:	GLUCAGONÄHNLICHES PEPTID 1 (GLP-1) VERBESSERT DIE BETA ZELLEN ANTWORT AUF GLUKOSE IN PATIENTEN MIT VERMINDERTER GLUKOSETOLERANZ	[2003/33]
	English:	GLUCAGON-LIKE PEPTIDE-1 (GLP-1) IMPROVES BETA-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE	[2003/33]
	French:	PEPTIDE 1 ANALOGUE AU GLUCAGON (GLP-1), PERMETTANT D'AMELIORER LA REPONSE DES CELLULES BETA AU GLUCOSE CHEZ DES SUJETS AYANT UNE DEFICIENCE DE LA TOLERANCE AU GLUCOSE	[2003/33]
	Former [2001/12]	GLUCAGONÄHNLICHE PEPTIDE VERBESSERT BETA ZELLEN ANTWORT ZÜR GLUKOSE IM PATIENTEN MIT BEHINDERTEN GLUKOSETOLREANZ
	Former [2001/12]	GLUCAGON-LIKE PEPTIDE-1 IMPROVES BETA-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE
	Former [2001/12]	PEPTIDE 1 RESSEMBLANT AU GLUCAGON, PERMETTANT D'AMELIORER LA CAPACITE DE LA CELLULE-G($g(b)) A DETECTER LE GLUCOSE ET D'Y REPONDRE CHEZ DES SUJETS SOUFFRANT DE TOLERANCE GLUCIDIQUE DEFICIENTE
Entry into regional phase	19.12.2000	National basic fee paid
	19.12.2000	Designation fee(s) paid
	19.12.2000	Examination fee paid
Examination procedure	05.01.2000	Request for preliminary examination filed International Preliminary Examining Authority: EP
	19.12.2000	Examination requested [2001/12]
	24.09.2002	Despatch of a communication from the examining division (Time limit: M04)
	17.01.2003	Reply to a communication from the examining division
	13.08.2003	Communication of intention to grant the patent
	10.12.2003	Fee for grant paid
	10.12.2003	Fee for publishing/printing paid
Divisional application(s)	EP04075402.0 / EP1419783
Opposition(s)	Opponent(s)	01 11.04.2005 19.04.2005 ADMISSIBLE Novo Nordisk A/S Novo Alle 2880 Bagsvaerd / DK Opponent's representative Thomas, Philip John Duval, et al, et al Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB
		[N/P]
	Former [2008/33]
	Opponent(s)	01 11.04.2005 19.04.2005 ADMISSIBLE Novo Nordisk A/S Novo Alle 2880 Bagsvaerd / DK Opponent's representative Thomas, Philip John Duval, et al, et al Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham NG1 5DD / GB
	Former [2005/22]
	Opponent(s)	01 11.04.2005 19.04.2005 ADMISSIBLE NOVO NORDISK A/S Novo Alle 2880 Bagsvaerd / DK Opponent's representative Thomas, Philip John Duval, et al, et al Eric Potter Clarkson Park View House, 58 The Ropewalk Nottingham NG1 5DD / GB
	23.05.2005	Invitation to proprietor to file observations on the notice of opposition
	23.11.2005	Reply of patent proprietor to notice(s) of opposition
	01.12.2005	Despatch of communication that the patent will be revoked
	11.12.2005	Legal effect of revocation of patent [2006/18]
Fees paid	Renewal fee
	14.05.2001	Renewal fee patent year 03
	14.05.2002	Renewal fee patent year 04
	13.05.2003	Renewal fee patent year 05
	13.05.2004	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]WO9808531 (LILLY CO ELI [US]) [X] 1,39,40 * page 23 - page 24 *;
		[X] - RACHMAN J ET AL, "Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.", DIABETOLOGIA, (1997 FEB) 40 (2) 205-11., XP002122529 [X] 1-38 * the whole document * DOI: http://dx.doi.org/10.1007/s001250050664
		[X] - CAVAGHAN M K ET AL, "Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.", JOURNAL OF CLINICAL INVESTIGATION, (1997 AUG 1) 100 (3) 530-7., XP002122530 [X] 1-38 * the whole document * DOI: http://dx.doi.org/10.1172/JCI119562
		[PX] - BYRNE M M ET AL, "Glucagon - like peptide 1 improves the ability of the beta - cell to sense and respond to glucose in subjects with impaired glucose tolerance.", DIABETES, (1998 AUG) 47 (8) 1259-65., XP002122531 [PX] 1-40 * the whole document * DOI: http://dx.doi.org/10.2337/diabetes.47.8.1259

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p